Stammdaten
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Unternehmen & Branche
| Name | Elicio Therapeutics, Inc. |
|---|---|
| Ticker | ELTX |
| CIK | 0001601485 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 199,6 Mio. USD |
| Beta | 1,88 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -39,571,000 | -2.58 | 25,862,000 | 1,636,000 | |
| 2025-09-30 | 10-Q | -10,083,000 | -0.60 | 28,284,000 | 3,816,000 | |
| 2025-06-30 | 10-Q | -10,561,000 | -0.66 | 29,528,000 | 1,834,000 | |
| 2025-03-31 | 10-Q | -11,209,000 | -0.87 | 28,144,000 | 8,904,000 | |
| 2024-12-31 | 10-K | -51,898,000 | -4.25 | 28,178,000 | -11,312,000 | |
| 2024-09-30 | 10-Q | -18,838,000 | -1.39 | 38,388,000 | -18,986,000 | |
| 2024-06-30 | 10-Q | -7,229,000 | -0.64 | 15,750,000 | -1,652,000 | |
| 2024-03-31 | 10-Q | -11,827,000 | -1.15 | 24,480,000 | 4,870,000 | |
| 2023-12-31 | 10-K | -35,195,000 | -6.96 | 27,146,000 | 11,373,000 | |
| 2023-09-30 | 10-Q | -10,658,000 | -1.27 | 30,987,000 | 13,286,000 | |
| 2023-06-30 | 10-Q | -7,559,000 | -2.61 | 37,619,000 | 23,557,000 | |
| 2023-03-31 | 10-Q | 0 | -8,029,000 | -24.77 | 41,767,000 | -109,876,000 |
| 2022-12-31 | 10-K | 2,301,000 | -28,208,000 | -89.27 | 22,664,000 | -102,145,000 |
| 2022-09-30 | 10-Q | 0 | -7,198,000 | -22.67 | 61,316,000 | -95,697,000 |
| 2022-06-30 | 10-Q | 653,000 | -7,299,000 | -23.20 | 70,813,000 | -88,616,000 |
| 2022-03-31 | 10-Q | 1,648,000 | -7,060,000 | -0.48 | 81,258,000 | -81,436,000 |
| 2021-12-31 | 10-K | 28,312,000 | -54,573,000 | -1.93 | 96,513,000 | -74,536,000 |
| 2021-09-30 | 10-Q | 1,460,000 | -15,704,000 | -0.53 | 109,940,000 | 64,514,000 |
| 2021-06-30 | 10-Q | 540,000 | -17,072,000 | -0.58 | 125,359,000 | 77,189,000 |
| 2021-03-31 | 10-Q | 371,000 | -36,687,000 | -1.56 | 139,200,000 | 92,443,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.